MedTrace Logo

Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast

NCT04102449 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-05-13

No results posted yet for this study

Summary

The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in patients with active psoriatic arthritis undergoing a treatment with Apremilast.

Conditions

Interventions

DRUG

Apremilast

Single arm receiving Apremilast and ultrasound examinations

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Medical University of Vienna

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Rusmir Husic, Dr. · Medical University of Graz

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-02-28
Completion
2022-02-28
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102449 on ClinicalTrials.gov